{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:19:39Z","timestamp":1789165179150,"version":"build-2803163510"},"reference-count":15,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Muscle and Nerve"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction\/Aims<\/jats:title>\n                    <jats:p>Rozanolixizumab, an inhibitor of the neonatal Fc receptor (FcRn), is used to treat patients with generalized myasthenia gravis (gMG) refractory to standard therapies. However, the approved six\u2010week cyclic regimen may be associated with a \u201cwearing\u2010off\u201d effect and disease fluctuations. We evaluated the non\u2010cyclic administration of rozanolixizumab in patients with complex gMG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively studied eight patients with anti\u2013acetylcholine receptor antibody\u2013positive complex\n                      <jats:styled-content style=\"fixed-case\">gMG<\/jats:styled-content>\n                      treated at Bordeaux University Hospital. \u201cComplex\u201d was defined by refractoriness, contraindications, intolerance to immunosuppressants or highly active\n                      <jats:styled-content style=\"fixed-case\">MG<\/jats:styled-content>\n                      . Patients transitioned to weekly or fortnightly rozanolixizumab after relapse during intermittent therapy. The primary outcome was \u2265\u20092\u2010point improvement in Myasthenia Gravis Activities of Daily Living (\n                      <jats:styled-content style=\"fixed-case\">MG<\/jats:styled-content>\n                      \u2010\n                      <jats:styled-content style=\"fixed-case\">ADL<\/jats:styled-content>\n                      ) score at 3\u2009months. Clinical data and serum immunoglobulin G (\n                      <jats:styled-content style=\"fixed-case\">IgG<\/jats:styled-content>\n                      ) levels were collected at baseline, 3, 6, and 12\u2009months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The cohort (mean age 70.5\u2009years; 75% female) had a mean baseline\n                      <jats:styled-content style=\"fixed-case\">MG<\/jats:styled-content>\n                      \u2010\n                      <jats:styled-content style=\"fixed-case\">ADL<\/jats:styled-content>\n                      score of 10.8, which improved rapidly to 4.1 at 3\u2009months. Hospitalization days dropped from 15.8\/month pre\u2010treatment to zero by 6\u201312\u2009months. Corticosteroids were tapered from 30.3 to 13.3\u2009mg\/day at 1\u2009year. Mean serum\n                      <jats:styled-content style=\"fixed-case\">IgG<\/jats:styled-content>\n                      levels declined by almost 50% and stabilized. Only one discontinuation occurred due to gastrointestinal symptoms; no serious infections or severe adverse events were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      Fortnightly rozanolixizumab yielded sustained clinical benefits, reduced hospitalizations, and enabled steroid tapering in complex\n                      <jats:styled-content style=\"fixed-case\">gMG<\/jats:styled-content>\n                      patients. This approach may prevent cyclical relapses seen with intermittent dosing. Larger studies are needed to confirm efficacy and long\u2010term safety.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mus.70274","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T03:46:30Z","timestamp":1779335190000},"page":"422-426","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Non\u2010Cyclic Rozanolixizumab Administration in Complex Generalized Myasthenia Gravis"],"prefix":"10.1002","volume":"74","author":[{"given":"Marc","family":"Abi Aoun","sequence":"first","affiliation":[{"name":"Neurology Department Robert Boulin Hospital  Libourne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Beauvais","sequence":"additional","affiliation":[{"name":"Neuromuscular Reference Center AOC, Neurology and Neuromuscular Diseases Department Pellegrin Hospital, Bordeaux University Hospitals  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marl\u00e8ne","family":"Barnay","sequence":"additional","affiliation":[{"name":"Neuromuscular Reference Center AOC, Neurology and Neuromuscular Diseases Department Pellegrin Hospital, Bordeaux University Hospitals  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010H\u00e9l\u00e8ne","family":"Violleau","sequence":"additional","affiliation":[{"name":"Neuromuscular Reference Center AOC, Neurology and Neuromuscular Diseases Department Pellegrin Hospital, Bordeaux University Hospitals  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Mathis","sequence":"additional","affiliation":[{"name":"Neuromuscular Reference Center AOC, Neurology and Neuromuscular Diseases Department Pellegrin Hospital, Bordeaux University Hospitals  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Duval","sequence":"additional","affiliation":[{"name":"Neuromuscular Reference Center AOC, Neurology and Neuromuscular Diseases Department Pellegrin Hospital, Bordeaux University Hospitals  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-6573","authenticated-orcid":false,"given":"Guilhem","family":"Sole","sequence":"additional","affiliation":[{"name":"Neuromuscular Reference Center AOC, Neurology and Neuromuscular Diseases Department Pellegrin Hospital, Bordeaux University Hospitals  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617749134"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231213240"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577\u2010022\u201000821\u20101"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(23)00077\u20107"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/22143602241308181"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.55.1.16"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2010025\u201012958\u20109"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14675"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(21)00159\u20109"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(24)00498\u20108"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532\u20105415.2000.tb02635.x"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16518"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70504"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/22143602241305511"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2025.2497840"}],"container-title":["Muscle &amp; Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.70274","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mus.70274","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.70274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:05:02Z","timestamp":1789164302000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.70274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/mus.70274"],"URL":"https:\/\/doi.org\/10.1002\/mus.70274","archive":["Portico"],"relation":{},"ISSN":["0148-639X","1097-4598"],"issn-type":[{"value":"0148-639X","type":"print"},{"value":"1097-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"2025-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}